Trial Profile

Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Biotech (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Proof of concept
Acronyms CURE-iv
Sponsors Kangstem Holdings

Most Recent Events

09 Nov 2021 Results of 5 year follow up assessing long term safety of Umbilical-cord-mesenchymal-stem-cell-therapy-Kangstem-Biotech presented at the ACR Convergence 2021
20 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
17 Mar 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com